AJOVista LLC Takes Position in Terns Pharmaceuticals, Inc. (NASDAQ:TERN)

AJOVista LLC purchased a new position in Terns Pharmaceuticals, Inc. (NASDAQ:TERN) during the fourth quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The institutional investor purchased 8,943 shares of the company’s stock, valued at approximately $58,000.

A number of other large investors also recently modified their holdings of TERN. Braidwell LP raised its holdings in shares of Terns Pharmaceuticals by 54.2% in the 3rd quarter. Braidwell LP now owns 2,840,052 shares of the company’s stock valued at $14,285,000 after acquiring an additional 997,700 shares in the last quarter. Affinity Asset Advisors LLC purchased a new stake in Terns Pharmaceuticals in the third quarter valued at approximately $1,635,000. Russell Investments Group Ltd. bought a new stake in Terns Pharmaceuticals during the fourth quarter valued at approximately $1,803,000. Graham Capital Management L.P. grew its stake in Terns Pharmaceuticals by 186.3% in the 3rd quarter. Graham Capital Management L.P. now owns 82,978 shares of the company’s stock worth $417,000 after buying an additional 53,998 shares in the last quarter. Finally, PEAK6 Investments LLC increased its holdings in shares of Terns Pharmaceuticals by 35.5% in the 3rd quarter. PEAK6 Investments LLC now owns 19,097 shares of the company’s stock worth $96,000 after buying an additional 5,000 shares during the last quarter. 98.26% of the stock is currently owned by institutional investors.

Insiders Place Their Bets

In other news, major shareholder Vivo Opportunity, Llc sold 181,117 shares of the business’s stock in a transaction that occurred on Monday, April 1st. The stock was sold at an average price of $6.99, for a total transaction of $1,266,007.83. Following the transaction, the insider now directly owns 275,772 shares of the company’s stock, valued at $1,927,646.28. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this link. Company insiders own 17.40% of the company’s stock.

Terns Pharmaceuticals Stock Up 1.1 %

Shares of TERN opened at $5.50 on Monday. The stock has a market capitalization of $355.71 million, a P/E ratio of -4.28 and a beta of -0.49. Terns Pharmaceuticals, Inc. has a twelve month low of $3.26 and a twelve month high of $13.51. The firm has a fifty day simple moving average of $6.12 and a two-hundred day simple moving average of $5.84.

Terns Pharmaceuticals (NASDAQ:TERN) last posted its earnings results on Thursday, March 14th. The company reported ($0.29) earnings per share for the quarter, hitting analysts’ consensus estimates of ($0.29). Sell-side analysts expect that Terns Pharmaceuticals, Inc. will post -1.46 EPS for the current fiscal year.

Wall Street Analyst Weigh In

A number of research firms recently commented on TERN. HC Wainwright reissued a “neutral” rating and issued a $5.50 target price on shares of Terns Pharmaceuticals in a research note on Tuesday, April 30th. JMP Securities reissued a “market outperform” rating and set a $15.00 price objective on shares of Terns Pharmaceuticals in a report on Tuesday, April 30th. BMO Capital Markets upped their target price on Terns Pharmaceuticals from $18.00 to $19.00 and gave the stock an “outperform” rating in a research note on Friday, March 15th. Finally, UBS Group decreased their price target on shares of Terns Pharmaceuticals from $19.00 to $18.00 and set a “buy” rating on the stock in a research note on Wednesday, March 27th. Two analysts have rated the stock with a hold rating and six have given a buy rating to the company. According to data from MarketBeat, the stock has an average rating of “Moderate Buy” and a consensus price target of $14.94.

Terns Pharmaceuticals Profile

Terns Pharmaceuticals, Inc, a clinical-stage biopharmaceutical company, develops small-molecule product candidates for the treatment of oncology, metabolic dysfunction-associated steatohepatitis (MASH), and obesity. The company develops TERN-701, an allosteric BCR-ABL tyrosine kinase inhibitor (TKI) that is in phase 1 clinical trial for chronic myeloid leukemia (CML), a form of cancer that starts in bone marrow.